Wave Life Sciences Ltd. - Ordinary Shares (WVE)
18.52
+0.00 (0.00%)
NASDAQ · Last Trade: Dec 9th, 4:37 AM EST
The company's investigational GLP-1 treatment performed admirably well in a phase 2b study.
Via The Motley Fool · December 8, 2025
We have an emerging new entrant in the increasingly crowded weight loss drug space.
Via The Motley Fool · December 8, 2025
Biggest Stock Movers Today, Dec. 8: CFLT, UL, & Morefool.com
Via The Motley Fool · December 8, 2025
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
Via Chartmill · December 8, 2025
Wave Life Sciences Stock Rockets 120% After Obesity Drug Shows Deep Fat Reduction, Muscle Gain — Traders See A ‘Blockbuster' Candidatestocktwits.com
Via Stocktwits · December 8, 2025
Via Benzinga · September 12, 2025
Wave Life Sciences Tumbled 19% Today, But Not Everyone’s Disappointed – Find Out Whystocktwits.com
Via Stocktwits · September 3, 2025
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday.
Via Chartmill · December 8, 2025
Wondering what's happening in Monday's pre-market session? Find an overview in this article.
Via Chartmill · December 8, 2025
December 3, 2025 – Capricor Therapeutics (NASDAQ: CAPR) has sent shockwaves through the biotech sector today, witnessing an astonishing 535% surge in its stock price, propelling the company to an eight-year high. The dramatic ascent follows the announcement of overwhelmingly positive top-line results from its pivotal Phase 3 HOPE-3 study for
Via MarketMinute · December 3, 2025
Via Benzinga · November 11, 2025
Wave Life Sciences (WVE) Earnings Transcript
Via The Motley Fool · November 10, 2025
Wave Life Sciences reported mixed Q3 2025 results, missing on revenue and EPS. Despite the financial miss, the biotech highlighted strong clinical progress for its obesity and AATD programs.
Via Chartmill · November 10, 2025
The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results that are validating extensive research and development efforts across the industry. Investors are demonstrating a renewed appetite for risk,
Via MarketMinute · November 7, 2025
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
Via Chartmill · October 29, 2025
Via Benzinga · October 29, 2025
Via Benzinga · October 15, 2025
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via Chartmill · September 3, 2025
Via Benzinga · September 3, 2025
Wave Life Sciences shares early WVE-006 trial results in alpha-1 antitrypsin deficiency, reporting durable protein production and favorable safety.
Via Benzinga · September 3, 2025
Via Benzinga · September 3, 2025
Via Benzinga · September 3, 2025
Today's session on Wednesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Via Chartmill · September 3, 2025